Replies to post #233928 on Biotech Values

[randychub]

Nice article. A lot of money at stake.


Based off the pricing precedent of just under $20, analysts with Bloomberg Intelligence calculated "a windfall of more than $15 billion revenue for Pfizer."

[biocqr]

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024671?articleTools=true

RESULTS
The mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID50) geometric mean titers of 501 in the 10-µg dose group and 3481 in the 100-µg dose group. Vaccination induced type 1 helper T-cell (Th1)–biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100-µg dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group.

CONCLUSIONS
Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.)